Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PB357
- Development stage
- Unknown
- Lead developer
- Puma Biotechnology
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
PB357 is an **irreversible tyrosine kinase inhibitor** under development for the treatment of cancer. It targets multiple members of the **ERBB receptor family**, specifically acting as an antagonist of the **epidermal growth factor receptor (EGFR, also known as ERBB1)**, **ERBB2 (HER2)**, and **ERBB4**. The molecule is classified as a small molecule antineoplastic agent. PB357 was originally developed by Pfizer and is now in-licensed and further developed by Puma Biotechnology. As of January 2024, clinical development is ongoing in Phase I for cancer indications, with the route of administration studied by intravenous delivery[1][3].
- Other names
- PB357PB-357PB 357
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)ERBB3 (Erb-b2 receptor tyrosine kinase 3)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB4 (Erb-b2 receptor tyrosine kinase 4)
Beyond the preview
Go deeper on PB357.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PB357.